Charles River Laboratories (CRL)

• Market cap: $7.77B
• 1 day: -0.77%
• 5 days: -7.31%
• 1 month: -14.65%
• 3 months: -22.81%
• 6 months: -23.45%
• Year to date: -16.78%
• 1 year: -37.99%
• 5 years: -13.88%
• 10 years: 106.09%
• Sector: Industrials
• Industry: Commercial Physical & Biological Research

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

2.35% less ownership

Funds ownership: 103.7% [Q2] → 101.36% (-2.35%) [Q3]

6% less funds holding

Funds holding: 657 [Q2] → 617 (-40) [Q3]

7% less capital invested

Capital invested by funds: $11B [Q2] → $10.3B (-$776M) [Q3]

25% less funds holding in top 10

Funds holding in top 10: 8 [Q2] → 6 (-2) [Q3]

26% less repeat investments, than reductions

Existing positions increased: 199 | Existing positions reduced: 269

32% less first-time investments, than exits

New positions opened: 66 | Existing positions closed: 97

38% less call options, than puts

Call options by funds: $59M | Put options by funds: $94.8M

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $175 15% upside
• Avg. target: $189 24% upside
• High target: $210 38% upside

5 analyst ratings

• positive: 1 20%
• neutral: 4 80%
• negative: 0 0%

Morgan Stanley Ricky Goldwasser 50% 1-year accuracy 8 / 16 met price target	21% upside $184	Equal-Weight Maintained	5 Feb 2025
JP Morgan Casey Woodring 0% 1-year accuracy 0 / 6 met price target	15% upside $175	Neutral Maintained	3 Feb 2025
Goldman Sachs Matthew Sykes 54% 1-year accuracy 21 / 39 met price target	25% upside $190	Buy Maintained	23 Jan 2025
UBS Dan Leonard 43% 1-year accuracy 3 / 7 met price target	22% upside $185	Neutral Downgraded	17 Jan 2025
B of A Securities Derik De Bruin 47% 1-year accuracy 9 / 19 met price target	38% upside $210	Neutral Maintained	13 Dec 2024